Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630067 · ClinicalTrials.gov registry record · Phase 1
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT04630067 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 105 participants.
The verdict
NCT04630067, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).
Interventions
- DRUG Placebo
- DRUG AZD3427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630067
The ClinicalTrials.gov registry entry for NCT04630067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04630067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04630067 about?
NCT04630067 is a clinical study titled "Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427". This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).
What is the current status of trial NCT04630067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2020-11-17. Estimated completion is 2022-09-14.
What interventions are being tested in trial NCT04630067?
The interventions under investigation include: Placebo (DRUG), AZD3427 (DRUG).
Who is sponsoring clinical trial NCT04630067?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.